Richard K Haynes

Centre of Excellence for Pharmaceutical Sciences, School of Health Sciences, North-West University, Potchefstroom, South Africa. e-mail

Department of Chemistry, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, e-mail haynes@ust.hk

Prof. Haynes received his Ph.D. degree in organic chemistry from the University of Western Australia, and conducted postdoctoral research at the University of Karlsruhe, Germany, and then at Imperial College, London. After academic appointments in the Department of Chemistry at Monash University, Melbourne, and then within the Department of Organic Chemistry at the University of Sydney, Prof. Haynes
moved to the Department of Chemistry at the Hong Kong
University of Science and Technology (HKUST) in 1993.

He currently is research professor at the Centre of
Excellence for Pharmaceutical Sciences, North-West
University, South Africa. Prof. Haynes participated twice in
the Australian Academy of Science-Chinese Academy of
Science Exchange Programmes. He served as external
member on the Chemotherapy of Malaria Committee,
within Tropical Diseases research (TDR), World Health
Organization (WHO), Geneva (1993-97) and then the
Drug Discovery Research Committee, TDR/WHO
(1998-2002). He collaborated on an artesunate
formulation project with Dr. Melba Gomes, TDR/WHO and
participated in the Australian Govt. AusAID Vietnam Malaria Control Project. He visited South Africa in 2007 and lectured at various institutions as a guest of the CSIR Pretoria Division of Biosciences hosted by Dr. Chris Parkinson.

In a collaborative program with Bayer AG, Leverkusen (1995-2007), he worked on development of the new artemisinin derivative artemisone that has now been taken over by the Indian Pharmaceutical Company Cipla. He is author of some 155 publications in the primary literature, 3 book chapters, has 38 world/individual patents, and has authored consulting reports for TDR/WHO, government agencies and industry.

Research interests include mechanism-based development of new agents for malaria, chemotherapy of other parasitic diseases, and mechanism-based cytotoxic agents for cancer chemotherapy. He is also engaged in mechanism-based synthesis of anti-infective agents designed to synergize effects of known redox active agents for tuberculosis and related mycobacterial infections. He is project manager of the South African Medical Research Council Project 2014-2017 MAL-TB REDOX - Development to the Clinical Phase of Oxidant and Redox Drug Combinations for Treatment of Malaria, TB and Related Diseases involving collaboration with institutions in South Africa and overseas.